BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 34545444)

  • 1. LI-RADS ancillary features favoring benignity: is there a role in LR-5 observations?
    Cannella R; Vernuccio F; Antonucci M; Gagliano DS; Matteini F; Midiri M; Brancatelli G
    Eur Radiol; 2022 Mar; 32(3):1804-1812. PubMed ID: 34545444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liver Imaging Reporting and Data System (LI-RADS) v2018: diagnostic value of ancillary features favoring malignancy in hypervascular observations ≥ 10 mm at intermediate (LR-3) and high probability (LR-4) for hepatocellular carcinoma.
    Cannella R; Vernuccio F; Sagreiya H; Choudhury KR; Iranpour N; Marin D; Furlan A
    Eur Radiol; 2020 Jul; 30(7):3770-3781. PubMed ID: 32107603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of Liver Imaging Reporting and Data System version 2018 ancillary features to upgrade from LR-4 to LR-5 on gadoxetic acid-enhanced MRI.
    Lee S; Kim SS; Bae H; Shin J; Yoon JK; Kim MJ
    Eur Radiol; 2021 Feb; 31(2):855-863. PubMed ID: 32809162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ancillary features in the Liver Imaging Reporting and Data System: how to improve diagnosis of hepatocellular carcinoma ≤ 3 cm on magnetic resonance imaging.
    Kang JH; Choi SH; Byun JH; Kim DH; Lee SJ; Kim SY; Won HJ; Shin YM; Kim PN
    Eur Radiol; 2020 May; 30(5):2881-2889. PubMed ID: 32020399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LI-RADS v2018: how to appropriately use ancillary features in category adjustment from intermediate probability of malignancy (LR-3) to probably HCC (LR-4) on gadoxetic acid-enhanced MRI.
    Jeon SK; Joo I; Bae JS; Park SJ; Lee JM
    Eur Radiol; 2022 Jan; 32(1):46-55. PubMed ID: 34132875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LI-RADS Version 2018 Ancillary Features at MRI.
    Cerny M; Chernyak V; Olivié D; Billiard JS; Murphy-Lavallée J; Kielar AZ; Elsayes KM; Bourque L; Hooker JC; Sirlin CB; Tang A
    Radiographics; 2018; 38(7):1973-2001. PubMed ID: 30289735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LI-RADS ancillary feature prediction of longitudinal category changes in LR-3 observations: an exploratory study.
    Shropshire E; Mamidipalli A; Wolfson T; Allen BC; Jaffe TA; Igarashi S; Higaki A; Tanabe M; Gamst A; Sirlin CB; Bashir MR
    Abdom Radiol (NY); 2020 Oct; 45(10):3092-3102. PubMed ID: 32052132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LI-RADS
    Chernyak V; Tang A; Flusberg M; Papadatos D; Bijan B; Kono Y; Santillan C
    Abdom Radiol (NY); 2018 Jan; 43(1):82-100. PubMed ID: 28647768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can modified LI-RADS increase the sensitivity of LI-RADS v2018 for the diagnosis of 10-19 mm hepatocellular carcinoma on gadoxetic acid-enhanced MRI?
    Xie S; Zhang Y; Chen J; Jiang T; Liu W; Rong D; Sun L; Zhang L; He B; Wang J
    Abdom Radiol (NY); 2022 Feb; 47(2):596-607. PubMed ID: 34773467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LI-RADS CT and MRI Ancillary Feature Association with Hepatocellular Carcinoma and Malignancy: An Individual Participant Data Meta-Analysis.
    Dawit H; Lam E; McInnes MDF; van der Pol CB; Bashir MR; Salameh JP; Levis B; Sirlin CB; Chernyak V; Choi SH; Kim SY; Fraum TJ; Tang A; Jiang H; Song B; Wang J; Wilson SR; Kwon H; Kierans AS; Joo I; Ronot M; Song JS; Podgórska J; Rosiak G; Kang Z; Allen BC; Costa AF
    Radiology; 2024 Feb; 310(2):e231501. PubMed ID: 38376399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LI-RADS v2018: utilizing ancillary features on gadoxetic acid-enhanced MRI to improve the diagnostic performance of small hapatocellular carcinoma (≤ 20 mm).
    Lyu R; Hu W; Wang D; Wang J; Gao Z; Jia K
    Abdom Radiol (NY); 2023 Jun; 48(6):1987-1994. PubMed ID: 36939913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gadoxetic acid-enhanced MRI of hepatocellular carcinoma: Diagnostic performance of category-adjusted LR-5 using modified criteria.
    Park JH; Chung YE; Seo N; Choi JY; Park MS; Kim MJ
    PLoS One; 2020; 15(11):e0242344. PubMed ID: 33186378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LI-RADS treatment response categorization on gadoxetic acid-enhanced MRI: diagnostic performance compared to mRECIST and added value of ancillary features.
    Kim SW; Joo I; Kim HC; Ahn SJ; Kang HJ; Jeon SK; Lee JM
    Eur Radiol; 2020 May; 30(5):2861-2870. PubMed ID: 32006170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Critical analysis of major and ancillary features of LI-RADS v2018 in the differentiation of small (≤ 2 cm) hepatocellular carcinoma from dysplastic nodules with gadobenate dimeglumine-enhanced magnetic resonance imaging.
    De Gaetano AM; Catalano M; Pompili M; Marini MG; Rodríguez Carnero P; Gullì C; Infante A; Iezzi R; Ponziani FR; Cerrito L; Marrone G; Giuliante F; Ardito F; Rapaccini GL; Vecchio FM; Giraldi L; Manfredi R;
    Eur Rev Med Pharmacol Sci; 2019 Sep; 23(18):7786-7801. PubMed ID: 31599447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of Liver Imaging Reporting and Data System 2017 (LI-RADS) Criteria for Imaging Diagnosis of Hepatocellular Carcinoma.
    Kierans AS; Makkar J; Guniganti P; Cornman-Homonoff J; Lee MJ; Pittman M; Askin G; Hecht EM
    J Magn Reson Imaging; 2019 Jun; 49(7):e205-e215. PubMed ID: 30257054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contrast-Enhanced Ultrasound Liver Imaging Reporting and Data System in Diagnosing Hepatocellular Carcinoma: Diagnostic Performance and Interobserver Agreement.
    Zhou H; Zhang C; Du L; Jiang J; Zhao Q; Sun J; Li Q; Wan M; Wang X; Hou X; Wen Q; Liu Y; Zhou X; Huang P
    Ultraschall Med; 2022 Feb; 43(1):64-71. PubMed ID: 32643777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Multicenter Assessment of Interreader Reliability of LI-RADS Version 2018 for MRI and CT.
    Hong CW; Chernyak V; Choi JY; Lee S; Potu C; Delgado T; Wolfson T; Gamst A; Birnbaum J; Kampalath R; Lall C; Lee JT; Owen JW; Aguirre DA; Mendiratta-Lala M; Davenport MS; Masch W; Roudenko A; Lewis SC; Kierans AS; Hecht EM; Bashir MR; Brancatelli G; Douek ML; Ohliger MA; Tang A; Cerny M; Fung A; Costa EA; Corwin MT; McGahan JP; Kalb B; Elsayes KM; Surabhi VR; Blair K; Marks RM; Horvat N; Best S; Ash R; Ganesan K; Kagay CR; Kambadakone A; Wang J; Cruite I; Bijan B; Goodwin M; Moura Cunha G; Tamayo-Murillo D; Fowler KJ; Sirlin CB
    Radiology; 2023 Jun; 307(5):e222855. PubMed ID: 37367445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does Training in LI-RADS Version 2018 Improve Readers' Agreement with the Expert Consensus and Inter-reader Agreement in MRI Interpretation?
    Zhang N; Xu H; Ren AH; Zhang Q; Yang DW; Ba T; Wang ZC; Yang ZH
    J Magn Reson Imaging; 2021 Dec; 54(6):1922-1934. PubMed ID: 33963801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic accuracy of prospective application of the Liver Imaging Reporting and Data System (LI-RADS) in gadoxetate-enhanced MRI.
    Kim YY; An C; Kim S; Kim MJ
    Eur Radiol; 2018 May; 28(5):2038-2046. PubMed ID: 29230525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incorporation of Ancillary MRI Features Into the LI-RADS Treatment Response Algorithm: Impact on Diagnostic Performance After Locoregional Treatment of Hepatocellular Carcinoma.
    Kim YY; Kim MJ; Yoon JK; Shin J; Roh YH
    AJR Am J Roentgenol; 2022 Mar; 218(3):484-493. PubMed ID: 34585608
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.